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Epigenetic Editing of Ascl1 Gene in 
Neural Stem Cells by Optogenetics
Chiao-Ling Lo1,*, Samrat Roy Choudhury2,*, Joseph Irudayaraj2 & Feng C. Zhou1,3
Enzymes involved in epigenetic processes such as methyltransferases or demethylases are becoming 
highly utilized for their persistent DNA or histone modifying efficacy. Herein, we have developed an 
optogenetic toolbox fused to the catalytic domain (CD) of DNA-methyltransferase3A (DNMT3A-CD) 
or Ten-Eleven Dioxygenase-1 (TET1-CD) for loci-specific alteration of the methylation state at the 
promoter of Ascl1 (Mash1), a candidate proneuron gene. Optogenetical protein pairs, CRY2 linked to 
DNMT3A-CD or TET1-CD and CIB1 fused to a Transcription Activator-Like Element (TALE) locating an 
Ascl1 promoter region, were designed for site specific epigenetic editing. A differentially methylated 
region at the Ascl1 promoter, isolated from murine dorsal root ganglion (hypermethylated) and striated 
cells (hypomethylated), was targeted with these optogenetic-epigenetic constructs. Optimized blue-
light illumination triggered the co-localization of TALE constructs with DNMT3A-CD or TET1-CD fusion 
proteins at the targeted site of the Ascl1 promoter. We found that this spatiotemporal association of the 
fusion proteins selectively alters the methylation state and also regulates gene activity. This proof of 
concept developed herein holds immense promise for the ability to regulate gene activity via epigenetic 
modulation with spatiotemporal precision.
DNA methylation defines the epigenetic state of the genome and has been associated with the transcriptional 
state of genes1. To date, a vast number of studies have aimed to measure DNA methylation levels as a means of 
gauging gene transcription and appraising biological status and disease conditions. However, beyond the rel-
ative terms of hypermethylation and hypomethylation, very less empirical information is available regarding 
the causal relationship between DNA methylation levels, transcriptional factor binding efficiency and eventual 
turnover of the transcriptional machinery. For example, questions relating to the effect of site-specific DNA meth-
ylation on the transcriptional state of a gene or the efficacy of transcriptional regulation on the distance between 
DNA methylation clusters (e.g. at CpG island distance) and the transcription start site (TSS) is unknown. More 
importantly, clarifying the role of DNA methyltransferases (DNMT) or Ten-Eleven Translocation dioxygenase 
(TET) enzymes in editing the DNA methylation marks in a site-specific manner or spanning CpG sites is criti-
cal for epigenetic programming. Our study aims to investigate this query by testing the feasibility of epigenetic 
editing and characterizing the key parameters of DNA methylation in relationship to transcription using an 
optogenetically-equipped epigenetic editing tool that functions at a gene promoter at a loci-specific resolution.
We adopted a novel approach that uses epigenetic editing with optogenetic tools to control gene expression. 
This approach involves the recruitment of epigenetic modifiers, comprising of DNMT3A or TET1, guided by 
Transcription Activation like Elements (TALE) to the selective methylation or demethylation sites at the pro-
moter of suppressed or inactive regulatory genes2,3. In particular, we report on our optogenetically engineered 
platform for site-specific epigenetic interventions of the Ascl1 gene (see below) by using the blue-light inducible 
dimerizing protein pair cryptochrome-2 and its interacting protein CRY2-CIB1 to ensure site and enzyme spec-
ificity and to monitor their role on gene expression.
Ascl1 (Mash1) is a proneuron gene essential for neuronal lineage and formation in the developing brain fol-
lowing the neuroprogenitor state4. Multipotent neural stem cell (NSC) differentiation into neurons and glial cells 
are subject to epigenetic regulation and transcription5. To test the aforementioned paradigm, we used two sets 
of rat NSCs, the rat dorsal root ganglion (DRG) and striatal (STR) NSCs6,7, with contrasting DNA methylation 
profiles at the promoter of the Ascl1 gene. In DRG NSCs, the Ascl1 gene is minimally methylated (also see Results) 
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throughout the gene and has previously been shown to preferentially yield neurons6,7, while in STR NSCs, Ascl1 
is methylated and preferentially yields glial cells8.
In our previous study, we demonstrated that selective epigenetic editing at the subtelomeric regions using 
optogenetic toolbox may significantly contribute to the telomeric length homeostais9. The optogenetic regulatory 
platform developed herein is demonstrated to selectively alter the endogenous epigenetic status of a proneuron 
gene namely Ascl1 in a site-specific manner, enabling the process of regulating transcription of Ascl1. We analyzed 
both DNMT3A and TET1, which modified DNA methylation in opposite directions at a distance of ~40 bp dis-
tance from their targeted binding sites. Targeted epigenetic alterations, even to a lesser extent, at 4 CpG sites in a 
strategic ~30 bp multi-transcription factor binding site was sufficient to regulate the transcription of Ascl1. Based 
on our findings, we found that both the level of DNA methylation and location of DNA methylation modifiers 
from the target sites are critical to transcriptional regulation, which is discussed as a highlight of the report.
Results
Ascl1 methylation and gene expression profile. Bisulfite amplicon sequencing at single base pair res-
olution of the entire Ascl1 gene including the 300 bp of the promoter region was conducted for the native DNA 
methylation profiles of the DRG NSCs and STR NSCs (Supplementary Table 1). We found that the DNA meth-
ylation profile for Ascl1 differs significantly between the two types of NSCs. The methylation levels of Ascl1 in 
DRG NSCs were low, mostly < 10%, throughout the gene body and at its promoter, in both undifferentiated and 
differentiated states. In contrast, the CpG methylation levels of Ascl1 in STR NSCs were much higher, in the range 
of between 30–50%; the highest level of methylation was observed at the 3′ end of the gene body and gradually 
decreased from the 3′ end to the 5′ end in the promoter in the undifferentiated state. General STR NSC meth-
ylation was decreased at the CpG island (p < 0.01) in differentiated state as compared to the undifferentiated 
state (Fig. 1a). We found that, at the extent of CpG island, there are four CpG clusters of differentially [DNA] 
methylated regions (DMRs) in the Ascl1 gene between undifferentiated and differentiated NSCs. The DMR-I is in 
the promoter, DMR-II is in the 5′ UTR, and DMR-III and DMR-IV are in the exon (Fig. 1a); each DMR has 3–4 
CpGs. For reasons indicated in next section, DMR-I was chosen as target for the methylation modification (see 
next section DMR Targeting). Furthermore, the distal DMR-III or IV was examined to demonstrate the range 
and specificity of TET and DNMT enzymatic effect. The minimally methylated DRG NSCs were targeted with 
DNMT3A, while the highly methylated STR NSCs were targeted with TET1.
We further found that the differential DNA methylation level between the two types of NSCs were also present 
with differential levels of Ascl1 expression, as obtained from a qRT-PCR analysis (Fig. 1b). In the undifferentiated 
Figure 1. DNA methylation and gene expression of rat Ascl1 in DRG and STR NSCs. (a) The gene structure 
of Ascl1 is shown on top of the figure. The dark blue box represents the exon, light blue boxes are untranslated 
regions (UTR), the blue line represents the intron, arrow indicates the direction of transcription, and the 
green box is CpG island. DNA methylation profiles for DRG and STR NSCs at both undifferentiated and 3-day 
differentiated stages (n = 3) were laid out corresponding to the gene structure. We sequenced a 2.3 kb region that 
spans the Ascl1 gene body and promoter regions (chr7: 28152247-28154486). The color of the box indicates the 
level of DNA methylation per the scale bar at the bottom of the figure. Red lines indicate statistically significant 
DMRs (p < 0.001) between STR-U (undifferentiated STR) and STR-D (3-day differentiated STR). (b) Relative 
gene expression level of Ascl1 in undifferentiated and 3-day differentiated DRG and STR neural stem cells 
(n = 4). The relative expression of Ascl1 was calculated using the Δ Δ Ct value. The average Ct values of target 
genes were normalized to the average Ct value of the internal control gene 18 s to calculate Δ Ct, and the Δ Δ 
Ct value was generated by normalizing the Δ Ct value of each cell line to the Δ Ct value of the undifferentiated 
DRG. The p-values between any two groups, except for undifferentiated DRG and differentiated STR, were all 
below 0.001. (c) Pyrosequenced region in the DMR-I of Ascl1 promoter contained 4 CpG sites. The first CpG 
site is 41 bp upstream of the TALE binding region. The sequenced region is 166 bp from the transcription start 
site (TSS) of Ascl1 (d) Predicted transcription factor binding sites in the sequenced region. **P < 0.01.
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state, the Ascl1 promoter was hypomethylated in DRG NSCs and hypermethylated in STR NSCs. Concurrent with 
our prediction, DRG NSCs expressed an 8.3-fold greater in the expression level of Ascl1 compared to STR NSCs. 
Furthermore, STR NSCs exhibited decreased DNA methylation in the DMR regions (Fig. 1a), and increased Ascl1 
expression on the third day of differentiation (Fig. 1b). These data cumulatively suggest a possible correlation 
between differential levels of DNA methylation to distinct gene expression between DRG and STR NSCs.
DMR and DMR targeting. The DMR-I was chosen for testing our hypothesis involving site-specific epige-
netic modifications (Fig. 1a) for the following reasons: (a) it contains the most significant methylation difference 
between DRG and STR NSCs, (b) it is in the promoter region, and (c) there are many (about 20) transcription 
factor (TF) binding sites at this DMR. DMR-I consists of four CpG sites (Rn5 Chr7: 28154421-28154454) in the 
Ascl1 promoter, and is 166 bp upstream of the TSS (Fig. 1c), which also contains several putative transcription 
factor-binding sites, including c-Fos, HES1 and E2F-1 (Fig. 1d) [obtained from the PROMO database (http://alg-
gen.lsi.upc.es/)10,11]. To target the DMR-I, we designed the TALE-locator to bind to a specific site, 41 bp upstream 
(chr7: 28154495-28154514) of the DMR-I region. The reasons for this consideration are as follows—(a) to avoid 
the possibility of targeted epigenetic enzymes masking the TATA box critical to the RNA polymerase binding, 
and (b) to determine the enzymatic coverage of nucleotide length by the TALE DNA binding module (Fig. 1c).
Construction and expression of optogenetic fusion protein. Two set of constructs, the site-specific 
DNA binding module (TALE module targeting upstream of DMR-I) and the epigenetic effector modules 
(DNMT3A- or TET1), were made for the desired editing of DNA methylation (see Designing the optogenetic 
constructs in the Methods Section). The native TALE module was designed to target a 20 bp site, upstream to the 
DMR-I, and was fused to the N-terminus of optically inducible cryptochrome-2-interacting binding protein-1 
(CIB1) protein to form the TALE-CIB1 fusion protein (~172kD), which also contained mCherry as a fluorescent 
reporter (Fig. 2a). In contrast, the epigenetic effector constructs were generated by fusing the catalytic domain of 
TET1 or DNMT3A to the N-terminus of CIB1 interacting protein cryptochrome-2 (CRY2) with the fluorescent 
reporter Enhanced Green Fluorescent Protein (EGFP), resulting in a TET1-CRY2-EGFP construct (~175 kD) for 
selective demethylation and a DMNT3A-CRY2-EGFP construct (~128 kD) for methylation (Fig. 2b,c). TALE-CIB1 
fusion proteins were co-transfected with either TET1-CRY2-EGFP or DNMT3A-CRY2-EGFP constructs, with similar 
transfection efficiency in both NSCs (~40% in the DRG and ~35% in STR NSCs) (Fig. 2f). After co-transfection 
with the locator (TALE-CIB1) and effectors (TET1-CRY2-EGFP or DNMT3A-CRY2-EGFP), we observed the excitation 
Figure 2. Ascl1 promoter targeting constructs. (a) Scheme of the TALE-CIB1 fusion protein (~172 kD) 
containing mCherry as the fluorescent marker. (b) Scheme of the TET1-CD-CRY2-EGFP (TET1-CRY2-EGFP) fusion 
protein (175 kD). (c) Scheme of the DNMT3A-CD-CRY2-EGFP (DNMT3A-CRY2-EGFP) fusion protein (128 kD). 
(d–f) Representative co-expressing TET1-CRY2-EGFP fusion protein (d, green) and TALE-CIB1-mcherry fusion 
protein (e, red) with merged image (f, orange and green) in a 2 day differentiated rat neuronal stem cell. We 
observed that TALE-CIB1 fusion proteins were predominantly expressed in the cytoplasm, while TET1-CRY2-EGFP 
fusion proteins were expressed throughout the whole cell body and axon. White arrow: axon. EF1a: Elongation 
factor 1-alpha promoter; NLS: nuclear localization signal; EGFP: Enhanced Green Fluorescent Protein.
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spectra of EGFP, or mCherry expression from the individually transfected cells or a combination of both the 
fluorophores from the co-transfected cells (Fig. 2d–f). We also observed the characteristic fluorescence emission 
spectra of EGFP and mCherry in the cell-free extract of the transfected cells (Inset; 2d-2f). From the fluores-
cent micrographs, we observed that TALE-CIB1 fusion proteins were predominantly expressed in the cytoplasm 
(Fig. 2e), while the epigenetic fusion proteins (TET1-CRY2-EGFP or DNMT3A-CRY2-EGFP) were expressed throughout 
the cells (Fig. 2d). The localization of fusion proteins was in agreement with a previous report12.
Optogenetic induction of Site-specific methylation. The changes in the levels of targeted methyl-
ation at the DMR-I of the Ascl1 promoter were further confirmed via pyrosequencing of the same region in 
both DRG (Fig. 3b) and STR (Fig. 4b) NSCs. The DRG harbored low levels of methylation (between 3–13%, 
Fig. 3b) and was used for methylation editing using DMNT3A-CRY2-EGFP (Fig. 3b), while STR exhibited charac-
teristically high levels of methylation (between 20–38%, Fig. 4b) and was used for demethylation editing using 
TET1-CRY2-EGFP (Fig. 4b).
Following blue light illumination (15 mW/cm2) for 3 hr, the co-transfected DRG NSCs with DMNT3A-CRY2-EGFP 
and TALE fusion proteins exhibited a significant increase in methylation level at three of the four CpG sites 
(CpG1, CpG2, and CpG4) in DMR-I as compared to the transfected but non-light treated groups (Transfection no 
light) (Fig. 3b). Quite effectively, all four CpGs in the co-transfected with light illumination (transfection w/light) 
DRG NSCs exhibited significant increase in methylation compared to the no-transfection group. In contrast, 
methylation in the designed off-target CpG sites, which were 58 bp upstream of DMR-IV, were not affected by the 
above transfections or light-stimulation (Fig. 3c,d).
In the demethylation editing study, the STR NSCs that were co-transfected with TET1-CRY2-EGFP and TALE 
fusion proteins (Fig. 4) and underwent illumination for 1 hour exhibited a significant decrease in methylation 
level at CpG2, CpG3, and CpG4 compared to the co-transfected, non-illuminated cells (Transfection no light) 
(Fig. 4b). Methylation in the co-transfected, non-illuminated cells, however, did not significantly differ from the 
no transfection groups. Similar to the study in DRG, the decrease in methylation in STR was only observed in the 
targeted DMR and absent from the off-target CpG sites near DMR-IV (Fig. 4c,d). We found that DNA methyl-
ation showed the biggest changes, optimized at 12-hour post-illumination as compared to 4-hour and 18- hour 
post-illumination recovery (Supplementary Figure 1). Therefore, the downstream analysis was assessed 12 hour 
after illumination. In STR cells, the cytotoxicity increased when illumination was over 2 hours, and the methyla-
tion change was more significant in cells with 1-hour of illumination compared to cells with 2-hour illumination; 
therefore, we used 1-hour light exposure as the optimized time of illumination.
Figure 3. Optogenetic induction of site-specific methylation in DRG cells using DNMT3A-CRY2-EGFP.  
(a) Pyrosequenced region at the TALE target sites of the Ascl1 promoter. The first CpG site is 41 bp upstream  
of the TALE binding region. The sequenced region is 166 bp from the transcription start site (TSS) of Ascl1  
(b) DNA methylation level of DNMT3A-CRY2-EGFP and TALE co-transfected DRG cells in the sequenced region 
illustrated in (a). (c) Pyrosequenced region at the non-TALE targeting site. This sequenced region is 1.2 kb 
upstream of TALE target sites, and contains 3 CpG sites. Methylation in non-TALE target region was accessed in 
(d) DNMT3A-CRY2-EGFP and TALE co-transfected DRG cells. The extent of changes in methylation was compared 
between Non-transfected, transfected with no light, and transfection with light groups. Student’s paired t-test 
with two tails was used for statistical analysis. Data are presented as the mean ± SEM. N = 5 for each group. 
*p < 0.05; **p < 0.01.
www.nature.com/scientificreports/
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Site-specific induction was associated with altered Ascl1 gene expression. Next, we determined 
the gene expression level of Ascl1, followed by epigenetic editing. Our results showed that, for the DRG NSCs, the 
transfection w/light group exhibited a site-specific increase in DNA methylation, and also resulted in a decrease 
in Ascl1 expression (Fig. 5a). Additionally, the decrease in DNA methylation previously observed in the STR 
transfection w/light groups resulted in a 2.5-fold increase in Ascl1 expression (Fig. 5b). In contrast, no significant 
difference in gene expression was observed between the No-transfection and Transfection no light groups in both 
DRG and STR NSCs, indicating that a change in Ascl1 expression was possibly due to the synergistic action of 
locator and effector constructs followed by blue-light illumination.
Figure 4. Optogenetic induction of site-specific methylation in STR cells using TET1-CRY2-EGFP. 
(a) Pyrosequenced region in the TALE target sites (b) DNA methylation level of TET1-CRY2-EGFP and TALE 
co-transfected STR cells in the sequenced region illustrated in (a). (c) Pyrosequenced region in non-
TALE targeting site. Methylation in non-TALE target region was accessed in (d) TET1-CRY2-EGFP and TALE 
co-transfected STR cells. The extent of changes in methylation was compared between No-transfection, 
transfection no light, and transfection with light. Student’s paired t-test with two tails was used for statistical 
analysis. Data presented as mean ± SEM. N = 5 for each group. #P < 0.1; *P < 0.05; **p < 0.01. 
Figure 5. Relative gene expression of Ascl1 in (a) DRG NSC co-transfected with DNMT3A-CRY2-EGFP and TALE 
(b) STR NSC co-transfected with TET1-CRY2-EGFP and TALE. The relative expression was calculated based on 
the Δ Δ Ct value. The average Ct values of target genes were normalized to the average Ct value of the internal 
control 18 s to calculate Δ Ct, and the Δ Δ Ct value was generated by normalizing the Δ Ct value of Transfection 
without light or Transfection with light group to the Δ Ct value of the No-transfection group. Student’s paired 
t-test with two tails was used for statistical analysis. Data presented as mean ± SEM. *p < 0.05; ** p < 0.01. n = 5 
for each group.
www.nature.com/scientificreports/
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Altered NeuN protein expression was associated with Optogenetic induction. We further exam-
ined the protein expression of the neuronal protein marker NeuN by immunocytochemistry (ICC) to determine 
whether the differentiation potential of NSCs could also be altered upon optogenetic modulation at the Ascl1 
promoter. STR transfection w/light cells, which exhibited increased Ascl1 expression, were expected to have a 
higher potency to differentiate into neurons and a lower potency to differentiate into glial cells, and we expected 
the opposite effects in DRG transfection w/light group. We quantified the ICC signal intensities from individual 
cells using the H-score method13. Based on our cumulative data, we observed a significant (p = 0.02) induction 
of NeuN expression in the STR transfection w/light cells comparing to the STR transfection without light group 
(Fig. 6). This indicates that site-specific editing of Ascl1 is leading alteration in neural stem cell fate determination.
Discussion
Design of Epigenetic Editing Tool. Advancing beyond the Zinc-finger protein-targeted DNA editing since 
200014, transcription-like effector nucleases (TALENs)15 and the Clustered regularly interspaced short palindro-
mic repeats (CRISPR)/Cas (a nuclease) system16–18 are being used for targeted cleavage of DNA for genetic editing. 
The concept of epigenetic editing is more complex than genetic editing not only because editing is upstream to the 
transcription, but also because epigenetic editing adds a few tiers of uncertainty, including the complexity of epi-
genetic enzymes, off-targeted binding due to their affinity to CpGs, functional epigenetic sites (location and range) 
and functional threshold of epigenetic changes. Nevertheless, targeted enzymatic modification such as DNA 
methylation is popular not only because of its potential to alter the epigenetic state but also offers a means to better 
understand the causal mechanism of epigenetic regulation on the transcription machinery. In epigenetic editing, 
the effectors (e.g. DNMTs, TETs, histone methyltransferases… etc.) are preferred to be fused to a DNA binding 
modules such as TALE-TFs or dCAS9 rather than DNA cleavage enzymes (e.g. FokI or Cas9 endonucleases). 
For example, to use the CRISPR system for epigenome editing, Cas9 is deactivated (dCas9) and fused with 
Figure 6. Protein expression of NeuN in (a) STR NSC no transfection control (b) STR NSC co-transfected with 
TET1-CRY2-EGFP and TALE without light treatment (c) STR NSC co-transfected with TET1-CRY2-EGFP and TALE 
with light treatment (d) Quantitate of the immunostaining images by H-score, where higher H-score represents 
higher protein expression among all the cells analyazed in the frame. Total eight images from four biological 
samples were analyzed for each group. All images were taken under the same parameters and magnitude 
(40X). Student’s t-test was used for statistical analysis. Data are presented as mean ± SEM. *P < 0.05; NoT: no 
transfection; TnL: Transfection no light; TL: Transfection with light.
www.nature.com/scientificreports/
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epigenetic modifiers, such as DNMT3A or TET119,20, and p30021, while guided RNA (gRNA) is used as the DNA 
binding module to manipulate the epigenome. For the present study, we decided to couple the optogenetic dimer-
izing protein pair CRY2 and CIB1 to the TALE over CRISPR-dCas9 mediated DNA binding modules (see Fig. 7). 
Previous reports have already reported a number of drawbacks of CRISPR-dCAS9 system, despite of their facile 
construction strategy and cost effectiveness. For example, the attachment of TAL-TF proteins to its target DNA 
binding site is more specific and dynamic, compared to dCAS9-TFs. This reduces the chance of non-specific 
(off-target) effects22. In contrast to dCAS9, TALE proteins could be directly fused to the effector domains, which 
allows for multiple targeting of distinct effectors including epigenetic modifiers across multiple loci23. In addition, 
a recent study demonstrated that TALE proteins causes higher enrichment of activating components (p300) and 
active histone markers (H3K27Ac) at the enhancer of Oct4 and Nanog gene loci, compared to CRISPR-dCAS9 
system, in the course of gene reactivation24. We provided a comparison of the tailor-use of TALE with the use 
of CRISPR-dCAS9 in Table 1. This Table will provide options for the investigators when choosing an optimal 
method for their own use.
Furthermore, the use of single fusion protein of TALE-TET for DNA demethylation2, TALE-DNMT for meth-
ylation25, or TALE- histone acetyltransferase/deacetylase for histone mark modification12 have been reported 
for epigenetic editing. With single fusion proteins, the effect of the epigenetic enzyme is uncontrolled and con-
stitutive (i.e. continuous). In comparison, with optogenetic constructs, we can periodically bring the epigenetic 
effector fusion protein to the target site. This provides us with a controlled and regulatory approach of epige-
netic regulation. In this study, we demonstrated a site-specific modulation of DNA methylation at the Ascl1 pro-
moter by introducing a pair of fusion protein constructs—containing either the catalytic domain of DNMT3A 
or TET1, while the target construct contained the TALE-CIB1 fusion protein that was inducible for 5mC/5hmC 
conversion or demethylation (Fig. 7). Each of the constructs contained an optogenetic component, CRY2 or 
CIB1, endowed with a blue-light inducible/reversible association involving effector-locator coupling, and enables 
site-specific epigenetic editing at spatiotemporal precision. Additionally, since success of co-transfection is critical 
for site-specific epigenetic editing, each of the constructs also contained a fluorescent protein marker (mCherry 
or EGFP) to report the presence and efficiency of the co-transfection.
Targeted Epigenetic Editing. In our study, we conducted site-specific epigenetic editing by TALE-targeting 
at a specific genomic location fused to methylation modifiers that were precisely coupled with optogenetic con-
trol. The fluorescent protein markers, incorporated in these constructs facilitated visualization of their intra-
cellular co-transfection. Interestingly, DNMT3A-CRY2-EGFP or TET1-CRY2-EGFP were initially diffused throughout 
cytoplasm, but begin to accumulate in the nucleus upon blue light exposure, which probably also facilitate intra-
nuclear coupling to their light mediated partner.
A concern relating for targeted editing using constitutive promoter-driven expression of effectors (DNMTs or 
TETs) that arose was that the binding nature of the effector would cause the transfected targeting construct to act 
non-specifically throughout many other off-target regions, rendering DNA methylation non-specific if the effec-
tor and locator is designed to yield one fusion protein. To nullify this possibility and ensure precise targeting, we 
adopted two approaches, such as (a) constructing two fusion proteins with optogenetic coupling or (b) developing 
only the catalytic (without the binding) domain of DNMT3A and TET1, which reduces the chance of their bind-
ing to the native off-target sites. The precise genomic targeting utilizing TALE is able to achieve DNA methylation 
modification specifically at 4 CpG sites at the proximal DMR-I (41 bp downstream) to the TALE-binding site, but 
not at CpG sites near DMR-IV (~1.2 kb downstream) to the TALE-binding site. Both hypermethylation by trans-
fected DMT3A-CRY2-EGFP and demethylation by transfected TET1-CRY2-EGFP demonstrated the proximal (Figs 3b 
and 4b) over the distal effect (Figs 3d and 4d) of epigenetic modifiers, and together validated the specificity of 
targeted epigenetic editing. In addition, we believe that through this system of paired optogenetic editing, a high 
resolution of epigenetic action at functional epigenetic sites (e.g. CpG sites) can be identified, responsible for the 
consequential transcription.
Functional Methylation Site. We assess the minimal CpG methylation alterations and the potential loca-
tion of these changes that might affect the transcription. With our optogenetic approach, we demonstrated that 
alteration of as few as 4 CpGs spanning ~30 bp DMR-I region was sufficient to alter the transcription of Ascl1. This 
was achieved by validating the proximal and distal CpG alterations and monitoring the transcriptional changes. 
Methylation with site-directed DNMT3A-CRY2-EGFP not only decreased Ascl1 gene expression, but also reduced 
TALE-TF CRISPR-dCas9 Ref.
Type of recognition Protein-DNA RNA-DNA
Specificity More specific and little off-target activity Higher tolerance to mismatches, less specific 22
Effector conjugation TALE could be directly fused with effector domain Effector could not be conjugated with sgRNA 23
Enrichment of effector at target site Feasible and efficient Not designed for 24
Complication with unwinding effect of DNA Not yet reported Yes, eg. Enhancer 24
Control of expression
For both methods, the expression is more constitutive. Upon co-transfection of dCAS9 
fused epigenetic proteins such as TET1 or DNMT3A and the single-guide RNAs 
(sgRNAs), there is always a possibility of uncontrolled and continuous epigenetic effect. 
The same is also true for the TAL fused epigenetic proteins.
Table 1. Comparison between TALE-TF and CRISPR0-dCas9 in the use for epigenetic editing.
www.nature.com/scientificreports/
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demethylation. In contrast, site-directed TET1-CRY2-EGFP increased Ascl1 gene expression, and decreased methyla-
tion in this DMR-I. Finally, phenotypic analysis of NeuN protein expression (a neuronal marker) also confirmed 
the possibility of site-specific epigenetic editing guiding neural specification. To our knowledge, this is the first 
demonstration of a combination of an optogenetic system with a site-specific DNA methylation editing platform 
to provide temporal control of the manipulation of DNA methylation using the TALE system in neuronal genes.
At least 15 transcriptional factor (TF) binding sites, including those of Hes1, Nkx2-1, HOXA5, E2F-1, MyoD, 
C/EBP family, STAT1, and c-Fos (see Fig. 1d), were predicted spanning the 30 bp sites including 4 CpGs. Given 
the binding partners of TFs and their individual functions, the picture of epigenetic regulation of transcription 
is likely more complex. For example, the DMRs, which involve enhancers at far upstream of promoters, may 
influence promoter regulation. DMRs in the gene body, such as in intronic regions or intron-exon junctions, 
may also affect alternative splicing if the splicing binding protein is epigenetically regulated. These “Functional 
Methylation Site” (FMS) may exist in each gene and may serve as a switch for the transcription. We advocate that 
FMS as small as of 3–4 CpGs in DMR critical to TFs binding could respond to environmental input and subject 
to transcriptional changes.
DNA methylation Threshold. By using a passive DNA demethylase (TET1) and DNA methyltrans-
ferase (DNMT3A), we showed that DNA methylation could either be increased or decreased at the same sites. 
With methylation altered by DNMT3A-CRY2-EGFP, we found an average of a 1.58-fold (1.38 to 1.92) increase in 
DNA methylation across all four CpG sites upon treatment with light, which was associated with a 1.75-fold 
reduction in Ascl1 gene expression. In contrast, when TET1-CRY2-EGFP was used in the STR cells, an average of 
1.1-fold decrease in DNA methylation was observed. Interestingly, although the change in DNA methylation by 
TET1-CRY2-EGFP is smaller than that by DNMT3A-CRY2-EGFP, we found a greater change in gene expression, which is 
~2.6-fold increase, by TET1-CRY2-EGFP.
One thing to note is that bisulfite pyrosequencing cannot differentiate 5-methylcytosine (5mC) from 
5-hydroxylcytosine (5hmC). Given that TET1 converts 5mC into 5hmC, and that 5hmC can lead to gene activa-
tion, we noticed the TET-1 induced demethylation is rather modest as compared with the prominent expression 
changes of Ascl1. It is likely that a combination of demethylation and a transformation for 5hmC occurred at this 
DMR. Also, it is possible that some of the methylation levels we detected in the STR co-transfected with light 
group were contributed by 5hmC, which likely is a result of the action of TET1-CRY2-EGFP. The 5hmC component 
and its contribution will be studied in a large yield of stem cells in our laboratory.
Of all the editing studies, we have seen a slight increase of methylation in part of the CpGs only by the DNMT 
construct with transfection but not light stimulation (Fig. 3b). Its elevation is quite small as compared to those 
with light stimulation. Nevertheless, we documented its occurrence. This is likely an efficient transfection resulted 
in undirected binding to the target site. Furthermore, the same TALE construct coupled with TET1CD did not 
resulted in methylation changes unless light stimulation was performed.
Figure 7. Schematic showing that the pair of fusion protein constructs—containing either the catalytic 
domain of TET1 (top panel) or DNMT3A (bottom panel), while the target construct contained the TALE-
CIB1 fusion protein. Each of the constructs contained an optogenetic component, CRY2 or CIB1, endowed 
with a blue-light inducible/reversible association involving effector-locator coupled to enable epigenetic editing. 
The association of TALE-CIB1 with TET1-CD-CRY2 induces conversion of 5mC into 5hmC or subsequent 
demethylation, while the association of TALE-CIB1 with DNMT3A-CD induces the addition of methyl group 
to unmethylated cytosines.
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Catalytic Range of DNA (De)methylation Enzymes. Our designed TALE bound to a region of Ascl1 
promoter (that is 240 bp to 260 bp upstream of the TSS), altered methylation of 4 CpG sites, which were 41 bp 
to 74 bp downstream of TALE binding sites (or − 166 to − 199 bp from TSS). This range of enzymatic activity is 
supported by previous finding demonstrating that the distance of altered methylation from target DNA sites was 
somewhere between 20 bp to 200 bp2,25. In our study, we only measured DNA methylation on the Watson strand. 
It is expected that similar levels on both strands as Maeder et al. demonstrated in their study2. Another interest-
ing point, is that the enzymatic activities of TET1-CRY2-EGFP and DNMT3A-CRY2-EGFP are likely to function at both 
ends of TALE target site due to a linker inserted in the fusion protein constructs that enables TET1-CRY2-EGFP or 
DNMT3A-CRY2-EGFP to flip between both ends. However, we were unable to measure methylation upstream of 
TALE binding sites because that region is relatively CG dense (5 CpGs in 20 bp), resulting in difficulties in primer 
design and sequencing.
We found reduced cell viability in STR cells after longer blue light exposure. The cytotoxicity was observed 
mainly in TET1-CRY2-EGFP transfected cells but not in DNMT3A-CRY2-EGFP transfected cells. We have tried up to 
3-hour light exposure for DNMT3A and have not observed similar finding. The cause is not clear, but apparently 
not due to the blue light. This effect may be specific to the catalytic domain of TET1. We have previously tried 
to transfect the full size construct of TET1 and DNMT3A, however the transfection efficiency of those were 
extremely low, therefore we pursue with TET1CD. Due the low transfection efficiency, at this point we cannot 
determine the toxicity effect between catalytic domain vs full length TET1. We may generate mutated catalytic 
domain as a comparison in the future.
In conclusion, epigenetic editing is far more complex than genetic editing, with multi-level considerations 
including the sites of action. Understanding how minimal changes in DNA methylation at identified strategic 
sites lead to gene expression not only facilitates a better understanding of how environmental input may “con-
veniently” alter an epigenetic “red button” to regulate the transcription of a specific gene, but also opens the door 
to learning more about how gene transcription can be harnessed through epigenetics. Our study, which used 
an optogenetic platform to demonstrate that a small DMR with a few CpGs in the promoter region of the Ascl1 
gene can be edited to change gene expression, helps to improve the understanding of targeted DNA methylation 
editing as an important component of epigenetic editing.
Methods
MiSeq profiling of Ascl1 DNA methylation. Three samples each, for both undifferentiated and 3-day 
differentiated and DRG and STR cells, were used for methylation profiling of the entire Ascl1 gene, including 
300 bp of the promoter region (RGSC 5.0/rn5 chr7: 28152246- 28154536). Extracted genomic DNA was treated 
with sodium bisulfite using the EZ DNA Methylation-Direct™ Kit (Zymo Research, Irvine, CA, Cat # D5020). 
We designed primers to amplify sequences ≤ 600 bp using the Zymo Bisulfite Primer Seeker program (http://
www.zymoresearch.com/tools/bisulfite-primer-seeker) and minimized the number of amplicons (Primers as 
listed in Supplementary Table 2). PCR amplification was carried out using hot-start DNA polymerase (AmpliTaq 
Gold, Life Technologies, Cat # 4311816). After amplification, all products were purified using DNA Clean & 
Concentrator™ -5 (Zymo Research, Irvine, CA, Cat #D4004) or other similar purification methods and quanti-
fied using a Turner Biosystems TBS-380 Mini-Fluorometer (Turner Biosystems, Sunnyvale, CA) with a fluores-
cent nucleic acid stain (Quant-iT PicoGreen dsDNA Assay Kit, Life Technologies, Cat # P7589) for quantitating 
double-stranded DNA to ensure that equimolar amounts were added for the Nextera XT sample preparation 
(Illumina, San Diego, CA) step. Each sample was given a unique index during enzymatic fragmentation and 
library preparation, according to standard protocols (Illumina, San Diego, CA). Different amplicons from each 
sample were pooled prior to Taqmentation, as each amplicon is distinguishable by sequence analysis. The pooled 
library was loaded into the MiSeq platform (Illumina, San Diego, CA) according to the Nextera XT protocol. 
MiSeq™ Reagent Kit v2 was used for the run.
Data analysis. The filtered Fastq data generated from MiSeq was analyzed at the Purdue Genomics Core 
Facility to trim off the index and adapter sequence. The CLC Genomics Workbench (Qiagen, Redwood City, CA) 
was used for further analysis. We used the completely methylated and fully unmethylated sequences as refer-
ences. We then mapped reads of each sample to both references under the following parameters: similarity frac-
tion = 0.9, length fraction = 0.5, nonspecific map-ignored. The rest of the parameters were set to default values. 
The mapped files were used for quality-based variant detection at frequency = 1%. For a CpG dinucleotide, if the 
Cytosine (C) was methylated, C was detected during variant detection. If the C was not methylated, it was con-
verted into Uracil (U) and then Thymine (T) during PCR; therefore, the nucleotide was referred to as T. We then 
determined the % methylation at each site for each sample by calculating the frequency of C to T.
Designing the optogenetic constructs. We modified the vector backbone of two light inducible (opto-
genetic) complementary fusion protein constructs, obtained from Addgene plasmid repository (https://www.
addgene.org/) and originally contributed by F. Zhang group. A full length (native) Transciption Activator Like 
Element (TALE) was designed to target the chosen site at the Ascl1 promoter (Fig. 7). The TALE module was 
synthesized by Genecopoeia, USA. The synthesized TALE along with a HA tag was then fused to the N-terminus 
of CIB1 (cryptochrome-interacting basic-helix-loop-helix) protein in the vector (#47458, Addgene). In addi-
tion, a mCherry coding sequence was fused to the C-terminus of the CIB1 sequence in the same vector. The 
optogenetic complement of the TALE fusion protein contained either the catalytic domain of TET1 (TET1-CD) 
or DNMT3A (DNMT3A-CD), fused to the N-terminus position of the cryptochrome-2 (CRY2) photolyase 
homology region (CRY2PHR)-EGFP fusion protein in the vector template (#47457). Inserts were incorpo-
rated into the vector backbone with a standard restriction-digestion based method. 100 ng of DNA were briefly 
PCR-amplified (CloneAmp HiFi PCR Premix (Clontech Laboratories Inc.) from their source plasmids, according 
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to manufacturer’s instructions. PCR-amplified inserts and the vector template were then digested with restriction 
endonucleases followed by gel purification using the QIAEX II gel extraction kit (QIAGEN). The purified vector 
and inserts were ligated with the requisite amount of T4 DNA ligase buffer and enzyme system (New England 
Biolabs) and kept at room temperature for 15 minutes. The ligated product was then transformed into stellar 
competent cells (Clonetech Laboratories Inc.) and plated out on an Ampicillin (Amp) supplemented LB agar 
plate. Suitable clones were propagated in LB-Amp+ media and the plasmids were extracted with QIAprep Spin 
Miniprep Kit (QIAGEN). The full-length nucleotide sequence of the fusion proteins can be found in the supple-
mentary information (supplementary sequence 1–3). The fusion protein was sequenced against a panel of primers 
as summarized in Supplementary Table 3, as well as sequencing primers (Supplementary Table 4) can be found 
in the supplementary results.
Cell culture, transfection, and illumination. Rat neural stem cells (NSCs) were isolated from the dorsal 
root ganglion (DRG) and striatum. This study utilized rat dorsal root ganglion (DRG)-derived NSCs and striatum 
(STR)-derived NSCs that were previously established and characterized in our laboratory as a bona fide NSC7,8. 
Multipotency and stability were tested and the epigenetic profiles were characterized in these screened NSCs7,26. 
DRG NSCs were previously shown to preferentially yield neurons6,7 while STR NSCs preferentially yielded 
non-neuronal glial cells8. Adult NSCs were maintained in Dulbecco’s Modified Eagle Medium/F-12 Nutrient 
Mix (DMEM/ F-12) media containing N2 supplement (12 μ L/mL, Life Technologies, Grand Island, NY), and 
penicillin-streptomycin (12 μ L/mL, Sigma, St. Louis, MO) and grown in a humidified incubator at 37 °C and 5% 
CO2. Media was supplemented with 10 ng/mL epidermal growth factor (EGF, Harlan Bioproducts for Science, 
Indianapolis, IN) and basic fibroblast growth factor twice a week (bFGF, PeproTech, Rocky Hill, NJ) for mainte-
nance of NSCs in the neurosphere form. During medium changes throughout the years, no passaging (trypsin 
digestion and cell transferring, except dividing into multiple flask) was performed. All neurospheres for analyses 
were screened by size < 1 mm shape (round neurosphere) for their robust growth.
For transfection, the undifferentiated neurospheres were mechanistically dissociated into small spheres via 
pipetting. Approximately 106 cells were used for one transfection. 100 ul of rat neural stem cell nucleofector 
kit (Lonza, Walkersville, MD), plus 5 ug of each plasmid constructs were used for co-transfection. The trans-
fection was performed using a Nucleofector 2b device (Lonza, Walkersville, MD) under program A-31 follow 
manufacture’s instruction. After 24 hours, the transfected cells were placed in fresh, warm culture medium, and 
assessed for expression of the construct under a fluorescent microscope. About 48 hours after transfection, the 
cells were seeded in a laminin (50 μ g/mL, Sigma) coated 35 mm culture dish, and supplemented with differenti-
ation medium consisting of Neurobasal media supplemented with 10% fetal bovine serum, 1.2% B27 and 1.2% 
penicillin-streptomycin. 24 hours after differentiation, the cells were treated with a mounted high-power LED 
blue light (455 nm) (Thorlabs), controlled by a DC2100 driver (Thorlabs), under the power of 15 mA (~0.6 mW/
cm2) for 1 hour for TET1/TALE co-transfected STR cells, and 3 hours for DNMT3A/TALE co-transfected cells. 
12-hour post-light treatment, the cells were collected by scraping from the Petri dish and were snap-frozen for 
DNA/RNA extraction.
RNA extraction and gene expression. Total RNA was isolated from each cell line using Qiagen 
RNeasy Mini Kit (Qiagen, Valencia, CA). An on-column DNA digestion was performed during RNA purifica-
tion using the Qiagen RNase-Free DNase Set (Qiagen, Valencia, CA). RNA quality and quantity was assessed 
using a Nanodrop spectrophotometer. 1 ug of RNA from each cell line was converted into cDNA using an ABI 
High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Grand Island, NY). 100 ng of cDNA was used 
as a template for qRT-PCR in combination with a TaqMan® Gene Expression Master Mix (Life Technologies, 
Grand Island, NY) and Taqman Gene-specific probes (Assay ID: Ascl1—Rn00574345_m1; 18 S—Rn03928990_
g1; S100b—Rn04219408; Rbfox3—Rn01464214_m1) on the StepOnePlus™ Real-Time PCR System (Life 
Technologies, Grand Island, NY). We assayed a minimum of four biological replicates for each group; cycling 
reactions were performed in duplicate. The relative expression of each gene was calculated based on the Δ Δ Ct 
value, where the results were normalized to the average Ct value of data from the 18 S housekeeping gene. We 
used Student’s paired t-test with two tails for statistical analysis. Data presented as mean ± SEM.
DNA extraction and Pyrosequencing. Genomic DNA was extracted from frozen cells with the DNeasy 
blood and tissue kit (Qiagen, Fremont, CA). 600 ng of the extracted genomic DNA was bisulfite converted, using 
the EZ DNA Methylation-Gold™ Kit (Zymo Research, Irvine, CA). Bisulfite-biotinylated primer specific PCR 
was carried out using the PyroMark PCR kit (Qiagen, Fremont, CA) follows manufacturer’s instruction. PCR 
products were pyrosequenced using PyroMark Q24 system (Qiagen) and Pyromark Q24 advanced CpG reagents 
(Qiagen, Fremont, CA) against region-specific primers (Supplementary Tables 5 and 6).
TF binding prediction. To predict putative transcription factor binding of the TALE target site in Ascl1 
promoter region, sequences of the TALE target region was retrieved from the RGSC Rnor_5.0 rat genome assem-
bly and were used as input to the PROMO database (http://alggen.lsi.upc.es/)10,11, which uses TRANSFAC for 
prediction. We presented the output from PROMO using the search criteria for species of Muridae (includes both 
mouse and rat).
Immunocytochemistry. The transfected and untransfected cells were subplated into 16-well chamber slides 
(ThermoFisher, Waltham, MA) coated with poly-D-lysine (20 mg/mL, Sigma, St. Louis, MO) and laminin (50 μ g/mL, 
Sigma, St. Louis, MO), and followed by the same culture condition and light treatment as described previously. 
12 hours post-light treatment, cells were fixed in 4% paraformaldehyde fixative for 24 hours, and then replaced 
with PBS.
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Immunostaining procedures followed a routine procedure as previously established for stem cell cultures in 
our laboratory8,26. In brief, endogenous peroxide was quenched with 3% H2O2 and 1% Triton X-100 was applied 
for 30 minutes to permeabilize the cell membranes, followed by incubation with 2 N HCl. Non-specific binding 
was blocked using 1.5% goat serum, plus 0.1% Triton X-100 in PBS. Primary antibody, rabbit α -NeuN, 1:250 (Cell 
Signaling Technology, Denvers, MA was incubated overnight at room temperature in the blocking buffer. The 
chamber wells were then incubated for 90 min in goat anti-rabbit IgG secondary antibodies conjugated with bio-
tin (Jackson ImmunoResearch, West Grove, PA) followed by rabbit Peroxidase-conjugated-streptavidin (Jackson 
ImmunoResearch, West Grove, PA) tertiary antibody for 90 min. The immunostaining was visualized by incuba-
tion of 0.05% 3′ -3′ diaminobenzidine (Sigma-Aldrich, St. Louis, MO) prepared at 1 μ g/1 mL and 1 mg/1 mL 3% 
H2O2 for 10 min, followed by a methyl green counterstaining. The slides were then imaged using a Leica Digital 
Microscope 6000B, Leica DC500 camera, and Firecam Imaging Software (version 1.7.1) (Leica Microsystems, 
Buffalo Grove, IL).
In order to quantify the staining intensities, ImageJ 1.48 (NIH, Bethesda, MD) was used. Representative wells 
were selected for each treatments and the intensity of each cell in the frame was measured at 40X objective. The 
image was first processed using the Color Deconvolution plugin (Gabriel Landini, 2007) with a similar protocol 
to Ruifrok et al.27. Then, cellular regions were selected using the ellipse tool. Cells that were not fully in the frame, 
had overlapping regions with other cells, or were in a cluster were omitted. The mean intensity of each region was 
used for comparison, and the H-score for each frame was calculated using the formula13
− = × + × + ×H Score A B C1 2 3
where A is the percentage of cells weakly stained, B is the percentage of cells moderately stained, and C is the per-
centage of cells strongly stained. The H-score formula thus gives the immunostaining a score from 0 to 300 while 
giving the cells with higher staining intensity higher weight.
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